Vanguard Global Advisers’s Celldex Therapeutics CLDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.1M Buy
34,020
+4,567
+16% +$175K ﹤0.01% 1652
2026
Q2
$1.1M Buy
29,453
+3,416
+13% +$110K ﹤0.01% 1696
2026
Q1
$826K Buy
+26,037
New +$710K ﹤0.01% 1762

Other funds holding CLDX

Vanguard Global Advisers's CLDX Position: Q3 2026 in Review

Vanguard Global Advisers increased its Celldex Therapeutics (CLDX) stake by 16% in Q3 2026, buying an estimated $175K and bringing the position to 34,020 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1652.

Vanguard Global Advisers first reported a position in CLDX in Q1 2026 and has held it in 3 quarters since. 249 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

  • Vanguard Global Advisers held 34,020 shares of Celldex Therapeutics worth $1.1M as of Q3 2026.
  • Vanguard Global Advisers bought 4,567 Celldex Therapeutics shares in Q3 2026, an estimated $175K.
  • Celldex Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #1652 holding.
  • Vanguard Global Advisers first reported a position in Celldex Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 249 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.